Wyeth Provides Status Update On TRIPHASIL-28 And ALESSE Oral Contraceptives

Main Category: Sexual Health / STDs
Also Included In: Women's Health / Gynecology
Article Date: 07 Aug 2006 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Wyeth (NYSE:WYE) announced that the company has designated both TRIPHASIL®-28 (levonorgestrel and ethinyl estradiol tablets-triphasic regimen) and ALESSE® (0.1 mg levonorgestrel/0.02 mg ethinyl estradiol tablets) oral contraceptives as temporarily out of stock (TOS). This TOS designation means that Wyeth is unable to re-supply these oral contraceptives. Communications regarding this status were sent to health care professionals, pharmacy managers and wholesalers. The Company is working diligently to address the product availability of TRIPHASIL-28 and ALESSE.

When current supplies of TRIPHASIL-28 and ALESSE at retailers are no longer available to consumers, patients should contact their prescribers about other contraceptive options.

As a leader in women's health care, Wyeth takes its responsibility very seriously. The Company will provide updates about TRIPHASIL-28 and ALESSE on www.wyeth.com as additional information becomes available.

For questions related to TRIPHASIL-28 and ALESSE, please contact Wyeth toll-free at 1-800-999-9384.

About Oral Contraceptives

Oral contraceptives are not for every woman. Most related side effects are not serious, and serious side effects occur infrequently. Serious risks of all birth control pills that can be life threatening include blood clots, stroke and heart attack. These risks are increased in women who smoke cigarettes, especially women over 35. Women who use oral contraceptives should not smoke.

Some women should not use oral contraceptives, especially women who have had a heart attack, stroke, blood clots, certain cancers or liver diseases, unexplained vaginal bleeding and those who are or may become pregnant. Oral contraceptives do not protect against HIV infection (AIDS) or sexually transmitted diseases.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third party-payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

http://www.wyeth.com